The H5N1 avian influenza virus continues to evolve into genetically diverse and highly pathogenic clades with increased potential for cross-species transmission. Recent scientific advances have included the development of next-generation vaccine platforms, promising antiviral compounds, and more sensitive diagnostic tools, alongside strengthened surveillance systems in both animals and humans. However, persistent structural challenges hinder global readiness. Vaccine production is heavily concentrated in high-income countries, limiting equitable access during potential pandemics. Economic and logistical barriers complicate the implementation of control strategies such as vaccination, culling, and compensation schemes. Gaps in international coordination, public communication, and standardization of protocols further exacerbate vulnerabilities. Although sustained human-to-human transmission has not been documented, the severity of confirmed infections and the rapid global spread among wildlife and domestic animals underscore the urgent need for robust preparedness. International organizations have called for comprehensive pandemic response plans, enhanced multisectoral collaboration, and investment in targeted research. Priorities include expanding surveillance to asymptomatic animal hosts, evaluating viral shedding and transmission routes, and developing strain-specific and universal vaccines. Strengthening global cooperation and public health infrastructure will be critical to mitigate the growing threat of H5N1 and reduce the risk of a future influenza pandemic.

Background/Objectives: Research across multiple disciplines has explored how nutrition is shaped by social isolation and feelings of loneliness, especially in the elderly population. Evidence from neuroscience highlights that loneliness may alter eating patterns, encouraging emotional eating or other compensatory food behaviors. Conversely, isolation from social contexts is often linked to a reduced variety of nutrient intake. This study set out to examine how psychosocial aspects, particularly social connectedness and feeling alone, relate to adherence to the Mediterranean diet among older adults residing in Sicily, southern Italy. Methods: Dietary habits of 883 adults were collected through food frequency questionnaires and assessed for adherence to the Mediterranean diet. Loneliness was measured through a targeted question from a standardized tool designed to capture depressive symptoms. Direct questions asked whether participants were engaged in social networks, such as family, friends and neighborhoods, or religious communities, in order to assess objective aloneness. Logistic regression analyses were performed to assess associations between variables of interest. Results: After accounting for potential confounders, both loneliness and aloneness showed an association with stronger adherence to the Mediterranean diet. Specifically, individuals experiencing loneliness and aloneness were less likely to have high adherence to the Mediterranean diet (OR = 0.28, 95% CI: 0.15, 0.51, and OR = 0.26, 95% CI: 0.12, 0.54, respectively). Conclusions: These findings underscore the importance of fostering social engagement among older populations, who may particularly benefit from maintaining active social ties to support healthier eating behaviors.

Obesity is increasingly recognized not only as a metabolic disorder, but also as a state of chronic low-grade inflammation that predisposes to systemic complications. Within this context, Dercum’s disease (DD), or adiposis dolorosa, emerges as a rare yet debilitating disorder characterized by painful subcutaneous lipomas, most commonly affecting middle-aged women. Despite its clinical impact, DD remains underdiagnosed and is often misclassified as lipedema, fibromyalgia, or lipomatosis, complicating prevalence estimates and hindering the development of targeted interventions. Current evidence suggests that DD represents a distinctive model of inflammatory obesity, where adipose tissue actively contributes to pain generation rather than serving as a passive fat reservoir. Histological and molecular findings point to adipose tissue dysfunction, immune cell infiltration, and elevated secretion of pro-inflammatory adipokines, signals which appear to fuel systemic low-grade inflammation, perineural immune interactions, and nociceptor sensitization. Peripheral mechanisms further shape the clinical phenotype. While familial clustering suggests possible genetic contributions, no definitive markers have been identified, and the role of obesity-induced epigenetic modifications remains unexplored. Therapeutic strategies remain largely symptomatic, including analgesics, antidepressants, physical rehabilitation, and surgical excision of lipomas, whereas molecularly targeted and diet-based interventions are still experimental. This article discusses the pathophysiology of DD, current treatments, and future perspectives, emphasizing that advancing patient registries, omics-based analyses, and interdisciplinary clinical trials will be crucial to elucidate disease mechanisms and guide novel therapies. Improved understanding of DD may not only enhance patient care, but also provide broader insights into the interplay between obesity, inflammation, and chronic pain.

Since surgery is a complex procedure due to multiple factors, it is more difficult to rigorously evaluate innovative processes in this field than clinical trials of new drugs. Being able to carry out an adequate study design with all its corresponding implications, achieving high-quality standards for these studies, ensuring respect for patients' rights, and verifying that their principles of beneficence, minimization of the risk of harm, justice and autonomy are a challenge for many researchers and professionals involved in the surgical process. Hence, it is advantageous to have guides that guarantee the methodological quality of research on innovative surgical procedures and that these guides include the ethical aspects involved in each of their stages. This review aims to make a historical overview of what has been published on the ethical approach to surgical innovation. In addition, the ethical aspects of the stages of the IDEAL framework for surgical innovation will be explained.

Myopathies represent a highly heterogeneous group of primary muscle disorders, traditionally classified based on clinical presentation and histopathological findings. Recent breakthroughs in molecular genetics, immunology, and pathophysiology have revolutionized the understanding, diagnosis, and management of these conditions. Both inherited and acquired forms of myopathy, including structural, metabolic, inflammatory, endocrine, and mitochondrial subtypes, are now recognized to arise from diverse pathogenic mechanisms such as impaired calcium handling, mitochondrial dysfunction, chronic inflammation, altered metabolism, and defective muscle regeneration. The advent of next-generation sequencing technologies has enabled more precise diagnosis of genetic forms, while the discovery of novel molecular biomarkers and immunological signatures offers promising avenues for disease monitoring and stratification across the broader spectrum. Importantly, molecular and mechanistic insights have redefined clinical classifications, allowing for better prognostic predictions and patient-tailored therapeutic approaches. Innovative treatments, including gene therapy, antisense oligonucleotide therapies, immune-modulating agents, metabolic support strategies, and targeted pharmacological interventions, are progressively translating molecular knowledge into clinical applications. However, technical limitations, biological variability, and ethical considerations continue to pose significant challenges to the implementation of precision medicine in myopathies. In this narrative review, we comprehensively discuss the latest molecular findings, their integration into clinical practice, and the emerging therapeutic strategies based on these discoveries. We also highlight current limitations and propose future research directions aimed at bridging the gap between molecular insights and effective, equitable patient care.